10 Result(s)

Article

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to asse...

Tommy A. Brown II, Elizabeth A. Mittendorf… in Breast Cancer Research and Treatment (2020)

Article

Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Sotirios P. Fortis, Michael Sofopoulos… in Journal for ImmunoTherapy of Cancer (2017)

Article

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

Sotirios P. Fortis, Michael Sofopoulos… in Journal for ImmunoTherapy of Cancer (2017)

Article

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...

Ioannis F. Voutsas, Eleftheria A. Anastasopoulou… in Journal for ImmunoTherapy of Cancer (2016)

Article

Immune profiling of breast cancer patients: relationship between tumour antigen T cell responses with suppressor and effector leukocyte populations

Nicole Janssen, Graham Pawelec, Lisa Speigl… in Journal for ImmunoTherapy of Cancer (2015)

Article

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine

Eleftheria A Anastasopoulou, Panagiotis Tzonis… in Journal for ImmunoTherapy of Cancer (2015)

Article

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

Recently, several types of immunotherapies have been shown to induce encouraging clinical results, though in a restricted number of patients. Consequently, there is a need to identify immune biomarkers to sele...

Eleftheria A. Anastasopoulou, Ioannis F. Voutsas… in Cancer Immunology, Immunotherapy (2015)

Article

The mannosylated extracellular domain of Her2/neu produced in P. pastorisinduces protective antitumor immunity

Her2/neu is overexpressed in various human cancers of epithelial origin and is associated with increased metastatic potential and poor prognosis. Several attempts have been made using the extracellular domain ...

Alexios Dimitriadis, Chrysanthi Gontinou, Constantin N Baxevanis… in BMC Cancer (2009)

Article

HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4⁺ T cell clones

HER-2/neu peptides recognized in the context of HLA-DR molecules by CD4⁺ Th lymphocytes on antigen-presenting cells have been identified. In this report, we demonstrate for the first time that HER-2/neu helper e...

Sonia A. Perez, Panagiota A. Sotiropoulou… in Cancer Immunology, Immunotherapy (2002)

Article

Genetic control of T-cell proliferative responses to Poly (Glu⁴⁰ Ala⁶⁰ ) and Poly (Glu⁵¹Lys³⁴Tyr¹⁵): Subregion-specific inhibition of the responses with monoclonal Ia antibodies

Constantin N. Baxevanis, Dorothee Wernet, Zoltan A. Nagy, Paul H. Maurer… in Immunogenetics (1981)